News & Blog

Recent Posts



ICA Will Be Sharing Your Voice with the FDA

ICA staff, board members, and IC patients will be heading to Washington, DC to speak at the Open Public Hearing (OPH) segment of the December 7, 2017 meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee at which the committee will discuss appropriate patient selection criteria and clinical trial design features, including acceptable endpoints, for demonstrating clinical benefit for drugs intended to treat interstitial cystitis and bladder pain syndrome. The committee will also discuss whether bladder pain syndrome and interstitial cystitis reflect overlapping or different populations, and whether it is appropriate to assess efficacy in the same way for both conditions. The recorded audio, slides, and other meeting materials will be made available on the FDA website approximately three weeks after the meeting.

View the ICA’s slides at

YOUR VOICES ARE BEING HEARD!!! Donate now, so ICA can represent the voices of IC patients throughout the year.